Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

NEW YORK, Feb.  26, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced additional interim data from its Phase I pharmacokinetic/pharmacodynamic (PK/PD) studies of Intranasal Racemic Ketamine (SLS-002).

Seelos Therapeutics  Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Feb.  13, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. The net proceeds to Seelos from this offering are expected to be approximately $4.3 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.

Seelos Therapeutics Announces  Closing of Public Offering of Common Stock

NEW YORK, Feb.  10, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock

NEW YORK, Jan.  28, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced an update to its Parkinson’s Disease program SLS-007.

Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007

NEW YORK, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced an update regarding its development programs for SLS-005 (trehalose) in Europe and the U.S. 

Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.

NEW YORK, Jan.  10, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced interim data from its Phase I study of Intranasal Racemic Ketamine (SLS-002).

Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the scheduling of a Type C meeting with the U.S. Food and Drug Administration (FDA) in March 2020.

Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)

NEW YORK, Dec.  04, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' U.S. Patent number 10,493,023 (Application number 14/889,727) titled: “TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE” (SLS-005).

Seelos Therapeutics Receives  Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 

Preliminary Data Expected in the First Quarter of 2020 Preliminary Data Expected in the First Quarter of 2020

Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)

Preliminary Data from Phase I DDI Study Expected in the First Quarter of 2020 Preliminary Data from Phase I DDI Study Expected in the First Quarter of 2020

Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).  “The decision by the FDA to grant Fast Track designation to SLS-002 underscores the significant unmet medical need for patients with Acute Suicidal Ideation and Behavior in Major Depressive Disorder,” said Raj Mehra, PhD, Chairman and CEO of Seelos. “We will be working diligently in close collaboration with the FDA to finalize the protocol for the proof of concept study and future clinical development.”  Tim Whitaker, MD, Head of R&D at Seelos added, “While I was a psychiatrist working in an academic teaching hospital, I saw and treated many of these patients. The limited medical treatment options have been a source of great frustration to patients, their families, and their healthcare practitioners. SLS-002 has promise to help address this critical unmet need. We are encouraged by the FDA's Fast Track designation as this moves the program forward in a meaningful way.”   According to the FDA, “Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.”    Data from a Phase I study of SLS-002 to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interactions (DDI) is expected in the first quarter of 2020.  About Suicide and Suicide Ideation   Suicide represents the 10th leading cause of death in the US across all age groups and ethnicities ( CDC 2018 ). Approximately 1.3 million adults attempt suicide each year in the US and 45,000 of such attempts result in death ( CDC 2018 ). Suicide occurs throughout the lifespan and was the second leading cause of death among 15- to 29-year-olds globally in 2016 ( WHO 2018 ). Prior suicide attempts are strongly correlated with a subsequent successful suicide (Johnsson-Fridell 1996), and the attempts themselves are predicted by suicidal ideation and planning ( Weissman 1989 ).  About Suicide and Major Depressive Disorder   Approximately 90% of all individuals who commit suicide suffer from a diagnosable psychiatric disorder ( Cavanagh 2003 ). While suicide ideation and behavior is most commonly associated with MDD, patients with other underlying Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses such as schizophrenia, personality disorders, bipolar disorder, and substance abuse disorders may also exhibit suicide ideation and behavior. It is estimated that the incidence of attempted suicide is about 20-fold higher in patients with MDD compared with the general population (Holma 2010;  Dadiomov 2019 ). Major depression is one of the most common mental disorders, with an estimated 17.3 million adults in the US (7.1% of all US adults) experiencing at least one major depressive episode in 2017 ( NIMH 2019 ).  About Fast Track Designation   A drug receiving  Fast Track  designation may eligible for the following:

Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov.  08, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update.  “Seelos continued to make significant progress in the third quarter on several of our programs”, said Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics. “We expect screening and dosing to commence in the phase IIb/III trial in Sanfilippo syndrome in the US for SLS-005, and in the PK/PD/DDI studies for SLS-002. As a result, we envision multiple clinical studies in these two programs next year. Getting these studies launched in consultation with the FDA, completing a financing, and ringing the opening bell at Nasdaq have kept us very busy and has continued to raise awareness of our company.”  “IND enabling work has also begun in SLS-008,” added Tim Whitaker, MD, Head of R&D. “We plan to study SLS-008 in a pediatric orphan indication, and we are exploring other potential target indications as well.”   Third Quarter Corporate Highlights

Seelos Therapeutics Reports Q3 2019 Pipeline Update

Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement

NEW YORK, Oct.  18, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019 London Healthcare Conference. The company will host One on One meetings in London, England on Wednesday, November 20th and Thursday, November 21st. 

Seelos Therapeutics to Participate in Upcoming Investor Conference in November

NEW YORK, Oct.  15, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead strategic regulatory consultant. Mr. Applebaum possesses over two decades of industry experience working with public and private companies handling regulatory interactions with the FDA and international regulatory agencies, global drug launches, company-wide corporate and legal affairs and merger and acquisition activities.

Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant

Company Will Host Meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies in NYC Company Will Host Meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies in NYC

Seelos Therapeutics to Participate in Upcoming Investor Conference in September

NEW YORK, Aug.  23, 2019  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 4,475,000 shares of common stock at a price of $1.50 per share in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement agents’ fees and other estimated offering expenses. The Company also agreed to issue to the investors unregistered warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement. The warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance.

Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering

Seelos to Proceed with Trial Enrollment and Dosing for Phase IIb/III Trial for Sanfilippo Syndrome Type A and B Patients Seelos to Proceed with Trial Enrollment and Dosing for Phase IIb/III Trial for Sanfilippo Syndrome Type A and B Patients

Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)

Seelos Therapeutics licensed gene therapy product SLS-004 from Duke University to treat patients with Parkinson's Disease.

Seelos' Gene Therapy Acquisition For Parkinson's Disease Brings Another Shot On Goal

Seelos announced they have a deal with Duke University to in-license a gene therapy program that is designed to take aim at Parkinson's disease.

Seelos Is A Speculative Buy With Parkinson's Gene Therapy Candidate

Seelos Therapeutics shares traded higher after news emerged the company acquired the license of gene therapy program to address Parkinson's disease from Duke University.

News for Seelos Therapeutics Stock (SEEL)